efalizumab   Click here for help

GtoPdb Ligand ID: 6593

Synonyms: anti alphaL integrin | antiCD11 alpha | hu1124 | Raptiva®
Approved drug Immunopharmacology Ligand
efalizumab is an approved drug (FDA (2003), EMA (2004))
Compound class: Antibody
Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
A peptide BLAST search using the heavy chain peptide sequence of efalizumab identifies sequence ID 5 in patent US6703018 [1] and data is presented from the monoclonal variant designated MHM24 F(ab)-8.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
integrin, alpha L subunit (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) Primary target of this compound Hs Antibody Binding 11.4 pKd - 1
⤷ pKd 11.4 (Kd 4x10-12 M) [1]
Description: Binding of humanized MHM24 to human CD11a on Jurkat cells.